Body composition and short-term mortality in patients critically ill with acute-on-chronic liver failure.
Acute-on-chronic liver failure
Body composition
Cirrhosis
Computed tomography
Intensive care medicine
Sarcopenia
Skeletal muscle index
Subcutaneous adipose tissue radiation attenuation
Visceral-on-subcutaneous adipose tissue ratio
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
10
2022
revised:
14
03
2023
accepted:
30
03
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Body composition is sex dependent and associated with an increased mortality risk in patients with cirrhosis. We evaluated whether it was also associated with short-term mortality in patients critically ill with acute-on-chronic liver failure (ACLF). We retrospectively included all patients with cirrhosis and ACLF hospitalised in the intensive care unit (ICU) of Lausanne University Hospital between 2010 and 2019 for whom an abdominal computed tomography (CT) scan performed ±7 days from admission was available. Patients from the ICU of Paul Brousse University Hospital admitted between 2017 and 2020 served as an external cohort. All body composition parameters at the third lumbar vertebral level (L3) were quantified using a deep learning-based method. In total, 192 patients from Lausanne were included. Median age was 62 years and 28-day survival rate was 58.2%. In males, variables independently associated with 28-day mortality on days 1 and 3 were Chronic Liver Failure Consortium (CLIF-C) ACLF-lactate and sarcopenia. In females, CLIF-C ACLF-lactate on days 1 and 3 was the only predictor of 28-day survival. We derived two scores combining sarcopenia and the CLIF-C ACLF-lactate score on days 1 and 3, with area under the receiver operating characteristic outperforming the CLIF-C ACLF-lactate score alone in male but not in female patients. Comparable results were found in the external cohort of 58 patients and supported the sex specificity of the performance of the model. Patients with sarcopenia had increased risks of invasive fungal infection and renal replacement therapy. Sarcopenia was associated with 28-day mortality in male but not in female patients critically ill with ACLF. Although screening for sarcopenia could impact the management of male patients, further studies are needed in female cohorts to investigate whether other body composition parameters are associated with outcomes. Body composition, easily assessed by CT, is altered in patients with cirrhosis and associated with outcome; it has never been investigated in patients critically ill with ACLF. The results of the present study, underlining the benefit of sarcopenia evaluation to improve prognosis prediction in males critically ill with ACLF, are of importance for physicians managing such patients to optimise the decision-making process toward continued treatment, liver transplantation, or limitation of care. In a wider sense, besides the number and course of organ failures, the results recall the weight of the general condition of males with ACLF at admission to ICU. In females critically ill with ACLF, in analyses limited by the sample size, none of the body composition parameters was associated with short-term mortality independently of organ failures; this suggests that the number and course of organ failures are the main determinant of mortality in these patients.
Sections du résumé
Background & Aims
UNASSIGNED
Body composition is sex dependent and associated with an increased mortality risk in patients with cirrhosis. We evaluated whether it was also associated with short-term mortality in patients critically ill with acute-on-chronic liver failure (ACLF).
Patients and methods
UNASSIGNED
We retrospectively included all patients with cirrhosis and ACLF hospitalised in the intensive care unit (ICU) of Lausanne University Hospital between 2010 and 2019 for whom an abdominal computed tomography (CT) scan performed ±7 days from admission was available. Patients from the ICU of Paul Brousse University Hospital admitted between 2017 and 2020 served as an external cohort. All body composition parameters at the third lumbar vertebral level (L3) were quantified using a deep learning-based method.
Results
UNASSIGNED
In total, 192 patients from Lausanne were included. Median age was 62 years and 28-day survival rate was 58.2%. In males, variables independently associated with 28-day mortality on days 1 and 3 were Chronic Liver Failure Consortium (CLIF-C) ACLF-lactate and sarcopenia. In females, CLIF-C ACLF-lactate on days 1 and 3 was the only predictor of 28-day survival. We derived two scores combining sarcopenia and the CLIF-C ACLF-lactate score on days 1 and 3, with area under the receiver operating characteristic outperforming the CLIF-C ACLF-lactate score alone in male but not in female patients. Comparable results were found in the external cohort of 58 patients and supported the sex specificity of the performance of the model. Patients with sarcopenia had increased risks of invasive fungal infection and renal replacement therapy.
Conclusion
UNASSIGNED
Sarcopenia was associated with 28-day mortality in male but not in female patients critically ill with ACLF. Although screening for sarcopenia could impact the management of male patients, further studies are needed in female cohorts to investigate whether other body composition parameters are associated with outcomes.
Impact and implications
UNASSIGNED
Body composition, easily assessed by CT, is altered in patients with cirrhosis and associated with outcome; it has never been investigated in patients critically ill with ACLF. The results of the present study, underlining the benefit of sarcopenia evaluation to improve prognosis prediction in males critically ill with ACLF, are of importance for physicians managing such patients to optimise the decision-making process toward continued treatment, liver transplantation, or limitation of care. In a wider sense, besides the number and course of organ failures, the results recall the weight of the general condition of males with ACLF at admission to ICU. In females critically ill with ACLF, in analyses limited by the sample size, none of the body composition parameters was associated with short-term mortality independently of organ failures; this suggests that the number and course of organ failures are the main determinant of mortality in these patients.
Identifiants
pubmed: 37547185
doi: 10.1016/j.jhepr.2023.100758
pii: S2589-5559(23)00089-7
pmc: PMC10403365
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100758Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
None of the contributing authors has any disclosures related to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Liver Transpl. 2017 Feb;23(2):143-154
pubmed: 28061014
JHEP Rep. 2019 Feb 23;1(1):53-65
pubmed: 32039352
Br J Radiol. 2019 Aug;92(1100):20190327
pubmed: 31199670
Nutrition. 2021 Nov-Dec;91-92:111417
pubmed: 34399402
Hepatology. 2021 Sep;74(3):1611-1644
pubmed: 34233031
Hepatology. 2019 Nov;70(5):1816-1829
pubmed: 31220351
Aliment Pharmacol Ther. 2016 Apr;43(7):765-77
pubmed: 26847265
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Clin Gastroenterol Hepatol. 2012 Feb;10(2):166-73, 173.e1
pubmed: 21893129
Nutrients. 2021 Jan 09;13(1):
pubmed: 33435310
Hepatology. 2019 Jan;69(1):258-269
pubmed: 30070381
J Hepatol. 2016 Dec;65(6):1232-1244
pubmed: 27515775
Inflamm Bowel Dis. 2019 Jan 1;25(1):67-73
pubmed: 29889230
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Crit Care. 2014 Jan 13;18(2):R12
pubmed: 24410863
Clin Nutr. 2019 Feb;38(1):48-79
pubmed: 30348463
Am J Transplant. 2022 Sep;22(9):2195-2202
pubmed: 35486028
Hepatology. 2016 Sep;64(3):986
pubmed: 26950268
Hepatology. 2017 Jun;65(6):2045-2058
pubmed: 28195332
N Engl J Med. 2020 May 28;382(22):2137-2145
pubmed: 32459924
J Clin Med. 2022 Jan 26;11(3):
pubmed: 35160063
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):864-869
pubmed: 29168629
Transplantation. 2019 Nov;103(11):2312-2317
pubmed: 30985575
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
Aliment Pharmacol Ther. 2019 Jul;50(1):75-83
pubmed: 31087566
Clin Nutr. 2020 Sep;39(9):2764-2770
pubmed: 31917051
Crit Care. 2018 Oct 10;22(1):254
pubmed: 30305132
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1165-1174
pubmed: 31389674
J Hepatol. 2022 Apr;76(4):983-985
pubmed: 34536432
Liver Transpl. 2017 May;23(5):625-633
pubmed: 28240805
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
J Hepatol. 2021 Jul;75 Suppl 1:S147-S162
pubmed: 34039486
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1757-1763
pubmed: 34423589
Cancers (Basel). 2022 Jan 05;14(1):
pubmed: 35008425
Crit Care Med. 2018 Nov;46(11):1783-1791
pubmed: 30106759
Liver Transpl. 2017 Nov;23(11):1451-1464
pubmed: 29072825
Hepatology. 2007 Jun;45(6):1348-54
pubmed: 17518367
Crit Care. 2013 Sep 19;17(5):R206
pubmed: 24050662
JHEP Rep. 2022 Apr 27;4(7):100495
pubmed: 35600667
Alcohol Clin Exp Res. 2017 Aug;41(8):1419-1431
pubmed: 28557005
Chest. 2019 Feb;155(2):322-330
pubmed: 30392790
Crit Care Med. 2010 Nov;38(11):2108-16
pubmed: 20802324
Liver Int. 2019 Jul;39(7):1271-1280
pubmed: 30825255
Clin Liver Dis. 2021 Feb;25(1):35-51
pubmed: 33978582
Liver Int. 2021 Apr;41(4):828-836
pubmed: 33280219
J Hepatol. 2012 Jan;56(1):95-102
pubmed: 21835136
J Hepatol. 2014 Jun;60(6):1151-7
pubmed: 24607622
Crit Care. 2016 Dec 1;20(1):386
pubmed: 27903267
Aliment Pharmacol Ther. 2019 Mar;49(6):807-813
pubmed: 30714184
PLoS One. 2019 Aug 8;14(8):e0220699
pubmed: 31393937